Skip to main content
SpringerLink
Log in

Teorie degenerativa e infiammatoria e ruolo della risposta immunitaria

  • Chapter
Aterosclerosi

  • 349 Accesses

Riassunto

Secondo questa teoria le alterazioni lipoproteiche, caratterizzate dall’ossidazione intravascolare delle LDL, contribuiscono in maniera rilevante a innescare e mantenere il processo infiammatorio aterogenetico. A questo proposito, diversi studi dimostrano che la riduzione dei livelli di colesterolo LDL plasmatico è fondamentale per diminuire il “carico aterogeno” negli anni e si associa a un significativo decremento degli eventi cardiovascolari [1]. La mortalità cardiovascolare è stata ridotta in seguito alla somministrazione di colestiramina, come evidenziato dallo studio LRC [2], e in seguito all’utilizzo di statine, come risulta dalle indagini WOSCOP [3], AFCAPS/TexCAPS [4], ASCOT-LLA [5], HPS [6] e più recentemente dal CARDS [7]. L’HPS, l’ASCOT e il CARDS hanno inoltre trattato migliaia di soggetti ultrasettantenni, rivelando che il “carico aterogeno” in individui anziani, ma senza pregressi eventi, si può ridurre vistosamente tenendo bassi i livelli di lipidi.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 19.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 32.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliografia

  1. Notarbartolo A (2005) Patogenesi “colesterolica” o “infiammatoria” dell’aterosclerosi: dilemma vero o fittizio? Ann Ital Med Int 20:63–68

    PubMed  Google Scholar 

  2. [No authors listed] (1984) The Lipid research Clinics Coronary Primary Prevention Trial results. JAMA 251(3):351–364

    Google Scholar 

  3. Shepherd J, Cobbe SM, Ford I et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301–1307

    Article  CAS  PubMed  Google Scholar 

  4. Downs JR, Clerfield M, Weis S et al (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis prevention study. JAMA 279:1615–1622

    Article  CAS  PubMed  Google Scholar 

  5. Sever PS, Dalhof B, Poulter NR et al (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the anglo-Scandinavian cardiac outcomes trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 361:1149–1158

    Article  CAS  PubMed  Google Scholar 

  6. Collins R, Armitage J, Parish S et al (2002) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361(9374):2005–2016

    Google Scholar 

  7. Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 364:685–696

    Article  CAS  PubMed  Google Scholar 

  8. Rubins HB, Robins SJ, Collins D et al (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341:410–418

    Article  CAS  PubMed  Google Scholar 

  9. Nissen SE, Tuzcu EM, Schoenhagen P et al (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291:1071–1080

    Article  CAS  PubMed  Google Scholar 

  10. Cannon CP, Braunwald E, McCabe CH et al (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes for the Pravastatin or Atorvastatin Evaluation and Infection Therapy. N Engl J Med 350:1495–1504

    Article  CAS  PubMed  Google Scholar 

  11. Nissen SE, Tsunoda T, Tuzcu EM et al (2003) Effects of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. A randomized controlled trial. JAMA 290:2292–2300

    CAS  Google Scholar 

  12. Schächinger V, Britten MB, Elsner M et al (1999) A positive family history of premature coronary artery disease is associated with impaired endothelium-dependent coronary blood flow regulation. Circulation 100:1502–1508

    PubMed  Google Scholar 

  13. Iwasa S, Fan J, Shimokama T et al (1999) Increased immunoreactivity of endothelin-1 and endothelin B receptor in human atherosclerotic lesions. A possible role in atherogenesis. Atherosclerosis 146:93–100

    CAS  Google Scholar 

  14. Xu CB, Zhang Y, Stenman E, Edvinsson L (2002) D-Erythro-N,N-dimethylspingosine inhibits bFGF-induced proliferation of cerebral, aortic and coronary smooth muscle cells. Atherosclerosis 164:237–243

    Article  CAS  PubMed  Google Scholar 

  15. Verreth W, De Keyzer D, Pelat M et al (2004) Weight loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptorgamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation 110:3259–3269

    Article  CAS  PubMed  Google Scholar 

  16. Barani J, Nilsson JA, Mattiasson I et al (2005) Inflammatory mediators are associated with 1-year mortality in critical limb ischemia. J Vasc Surg 42:75–80

    Article  PubMed  Google Scholar 

  17. Psaty BM, Furberg CD (2005) COX-2 inhibitors-lessons in drug safety. N Engl J Med 352:1133–1135

    Article  CAS  PubMed  Google Scholar 

  18. Pasqui AL, Bova G, Maffei S et al (2005) I mediatori della risposta immunitaria nell’aterosclerosi. Ann Ital Med Int 20:81–89

    PubMed  Google Scholar 

  19. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135–1143

    Article  CAS  PubMed  Google Scholar 

  20. Caligiuri G, Paulsson G, Nicoletti A et al (2000) Evidence for antigen-driven T cell response in unstable angina. Circulation 102:1114–1119

    CAS  PubMed  Google Scholar 

  21. Hansson GK (2001) Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 21:1876–1890

    Article  CAS  PubMed  Google Scholar 

  22. Prasad A, Zhu J, Halcox JP et al (2002) Predisposition to atherosclerosis by infections: role of endothelial disfunction. Circulation 106:184–190

    Article  PubMed  Google Scholar 

  23. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH (2003) Molecular mechanisms regulating Th1 immune responses. Ann Rev Immunol 21:713–758

    Article  CAS  Google Scholar 

  24. Lien E, Ingalls RR (2002) Toll-like receptors. Crit Care Med 30:S1–S11

    Article  CAS  Google Scholar 

  25. Mayr M, Kiechl S, Willeit J et al (2000) Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori and Cytomegalovirus with immune reactions to Heat-Shock Proteins 60 and carotid or femoral atherosclerosis. Circulation 102:833–839

    CAS  PubMed  Google Scholar 

  26. Xu Q (2002) Role of heat shock proteins in atherosclerosis. Arterioscler Thromb Vasc Biol 22:1547–1559

    Article  CAS  PubMed  Google Scholar 

  27. Zal B, Kaski JC, Arno G et al (2004) Heat-shock protein 60-reactive CD4+ CD28 null T cells in patients with acute coronary syndromes. Circulation 109:1230–1235

    Article  CAS  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Italia

About this chapter

Cite this chapter

(2010). Teorie degenerativa e infiammatoria e ruolo della risposta immunitaria. In: Aterosclerosi. Springer, Milano. https://doi.org/10.1007/978-88-470-1412-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-1412-1_7

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-1411-4

  • Online ISBN: 978-88-470-1412-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation